Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 166

Results For "UP"

7688 News Found

Mumbai doctors perform India’s first robotic surgery to fix rare uterine defect in 23 year old
Hospitals | March 10, 2026

Mumbai doctors perform India’s first robotic surgery to fix rare uterine defect in 23 year old

Doctors recommended a robotic Strassmann Metroplasty, a reconstructive surgery that joins the two halves of the uterus into a single cavity capable of supporting pregnancy


Codis expands UK manufacturing with groundbreaking spray dryer
Medical Device | March 10, 2026

Codis expands UK manufacturing with groundbreaking spray dryer

The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027


Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
News | March 10, 2026

Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development

The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications


Mosaic Clinical Technologies’ AI breakthrough earns FDA “Breakthrough Device” designation
Medical Device | March 10, 2026

Mosaic Clinical Technologies’ AI breakthrough earns FDA “Breakthrough Device” designation

Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings


Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens
News | March 10, 2026

Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens

The first of four planned modules at the new plant is expected to come online by summer 2026


FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis
Drug Approval | March 10, 2026

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials


Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer
Biotech | March 10, 2026

Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer

The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients